IOL Chemicals to launch APIs in US market
IOL Chemicals and Pharmaceuticals has received US FDA approval for marketing APIs in US after successful inspection of its ibuprofen manufacturing facility situated at Barnala in Punjab. The said facility at Barnala has also been approved by ANVISA Brazil, WHO and MOH Japan. These approvals will help to build and sustaining the growth by its API business in coming years.
The company's manufacturing facility already hold Certificate of Suitability for its products ibuprofen, metformin hydrochloride and lamotrigine from European Directorate for the Quality of Medicines and HealthCare (EDQM) authorities Council of Europe, France.